Medidata Solutions Broadens CRO Partner Accreditations to Field Increasing Product Demand
Addition of Seven Accreditation Options Enables Services Partners to Support Wide Range of Medidata Clinical Research Technologies
Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that it has expanded its accreditation program for services partners to include seven additional Medidata products, in response to the increasing global demand for its product portfolio. The accreditations are available through the Medidata Partner Program, which selects and enables leading contract research organizations (CROs) and other service providers to manage sponsors’ clinical trials using Medidata products.
Since 2007, Medidata has offered partner accreditations for its Medidata Rave ® electronic data capture (EDC) and clinical data management (CDM) system, providing end user training, user and site administration, study build, reporting, outputs and migration services. With the growing number of global research sponsors implementing a range of Medidata products across the clinical development process, Medidata added the following accreditation options for Medidata Services Partners :
- Medidata Balance ™— Partners are enabled to provide randomization and trial supply management (RTSM) services using this innovative system. Investigators can access one system—Medidata Rave—for EDC, randomization and supply management.
- Medidata Coder ™— Partners offer medical coding services using this centralized enterprise coding solution that is easily integrated with any source system for accelerated coding activities.
- Medidata CTMS ™— Partners can offer trial management services using modular and flexible tools for study planning, start-up and conduct, along with financial management and trial monitoring. Sponsors benefit from faster site payments, more timely monitor reporting and better visibility into trial milestones.
- Medidata Designer ® — Partners offer study design services leveraging this innovative study and protocol design solution based on reusable libraries and structured design information to improve protocol quality, expedite EDC setup and reduce amendments.
- Medidata Grants Manager ® — Partners use this trial budgeting tool for exclusive access to the PICAS® database of negotiated costs from investigator grants to rapidly provide customers with accurate trial forecasts and budgets for clinical trials.
- Medidata Rave Safety Gateway — Partners automate their customers’ EDC-to-safety-system data transfers using this system to expedite case triage with improved accuracy and completeness of SAE case data, reduce data reconciliation activities and eliminate error-prone phone, paper and fax processes.
- Medidata Rave Targeted SDV — Partners can offer more efficient monitoring services using this EDC-based solution to execute targeted (risk-based) source document verification.
“As we continue to develop and enhance our product portfolio, there is a growing need to provide outsourcing organizations with the flexibility to add services that best complement their capabilities,” said Graham Bunn, vice president of partnerships, Medidata Solutions. “With these new accreditations, we can better enable our partners to provide greater value to sponsors on their outsourcing services, ultimately strengthening their strategic relationships.”
Medidata trains, accredits and supports Medidata Services Partners on its technology so partners can cost-effectively implement and use Medidata products for sponsors’ studies, allowing them to quickly realize the benefits of this technology. To become accredited, an organization must first complete required training with a Medidata services team to learn best practices for implementing and using the product. After demonstrating know-how and experience with specific products, Medidata recognizes the organization as a Medidata Services Partner.
Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer services in support of Medidata products. Since then, the program has grown to include about 30 partners, ranging from smaller clinical consultancies to large, global CROs.
About Medidata Solutions Worldwide
Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
Contact:
Lois Paul & Partners
Susan McCarron, 617-986-5767
Susan_McCarron@lpp.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 09:28:00 CEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom